Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib vs Imatinib for Treatment-free Remission in CP-CML
NCT02602314Phase 4Unknown
- Sponsor
- GIMEMA
- Start
- Nov 2016
- Primary completion
- Feb 2023
- Countries
- 2
01
Overview
A Phase 4 trial of nilotinib in chronic myeloid leukemia (CML), sponsored by GIMEMA. Status: unknown.
02
Drugs
nilotinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT02602314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02602314.